Cytosorbents Corp Stock Price, News & Analysis

B. Braun Avitum AG and CytoSorbents Corporation (NASDAQ: CTSO) have established a global co-marketing agreement to promote CytoSorb^® in conjunction with B. Braun's OMNI^® continuous blood purification platform. This partnership aims to leverage B. Braun's advanced medical technology to enhance the treatment of severe inflammation by utilizing the CytoSorb^® adsorber, already CE Mark certified and available in 67 countries. Financial details of the agreement were not disclosed.

CytoSorbents Corporation (NASDAQ: CTSO) will announce its Q4 2020 and fiscal 2020 financial results on March 9, 2021 at 4:45 PM EST. Management will host a conference call to discuss operational and financial achievements, as well as a Q&A session. CytoSorbents specializes in critical care immunotherapy with its flagship product, CytoSorb®, approved in the EU, utilized in over 121,000 treatments worldwide. The company has received significant funding of over $38 million for its innovative blood purification technologies.

CytoSorbents Corporation (NASDAQ: CTSO) will participate in the Cowen 41st Annual Health Care Conference on March 3, 2021. CEO Dr. Phillip Chan will provide insights into the company's advancements and future outlook, followed by a discussion with Dr. Joshua Jennings of Cowen. The company has made significant progress in critical care immunotherapy with its CytoSorb® blood purification technology, already utilized in over 121,000 human treatments. This technology is designed to treat severe inflammatory conditions and is approved in the EU, distributed across 67 countries.

CytoSorbents Corporation (NASDAQ: CTSO) announced a strong performance in 2020 with a preliminary revenue of $40.8 million, a 73% increase from 2019. The company aims for sales growth in 2021, focusing on U.S. FDA approval for CytoSorb to remove ticagrelor in cardiothoracic surgeries. The company plans to expand its manufacturing capacity and has already achieved FDA Emergency Use Authorization for CytoSorb in treating critically-ill COVID-19 patients. Upcoming earnings details will be disclosed on March 9, 2021.

CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. CEO Dr. Phillip Chan will engage in a fireside chat with Danielle Antalffy, highlighting the company's progress and future outlook. CytoSorbents specializes in critical care immunotherapy and its flagship product, CytoSorb®, is widely used for blood purification in critically ill patients. The technology is approved in the EU and has been utilized in over 121,000 treatments globally.

CytoSorbents Corporation (NASDAQ: CTSO) has received recognition from the UK's National Institute for Health and Care Excellence (NICE) regarding its CytoSorb blood purification technology. The Medtech Innovation Briefing highlights the ability of CytoSorb to reduce bleeding risks in cardiac surgery by eliminating the blood thinner ticagrelor. NICE's analysis indicates potential cost savings of £3,941 per procedure and shorter hospital stays. Dr. Efthymios Deliargyris noted its game-changing potential, emphasizing the importance of strong clinical evidence for adoption.

CytoSorbents Corporation (NASDAQ: CTSO) announced the appointment of David D. Cox, Ph.D., MBA, as Vice President of Global Regulatory Affairs. Dr. Cox, who previously held a similar role at Integra LifeSciences, has extensive experience in regulatory approvals, including FDA submissions for medical devices. His primary focus will be to expedite U.S. FDA approval for CytoSorb's use in removing ticagrelor during cardiac surgery, a process that has received Breakthrough Device designation. This leadership change is expected to enhance regulatory strategy and facilitate entry into the lucrative U.S. market.

CytoSorbents Corporation (NASDAQ: CTSO) has received approval from the Korean Ministry of Food and Drug Safety for its CytoSorb blood purification technology. This approval allows treatment for various conditions, including cytokine storms, liver disease, and trauma, in a healthcare system serving nearly 52 million people. This marks a significant milestone in expanding CytoSorb's reach, now available in 67 countries. The partnership with Fresenius Medical Care Korea aims to enhance critical care and addresses rising sepsis mortality rates in the region.

CytoSorbents Corporation (NASDAQ: CTSO) has received Health Canada authorization for its CytoSorb® blood purification technology for use in COVID-19 patients. CytoSorb is now commercially available in Canada and has received approvals in 67 countries worldwide. This authorization allows for emergency use in hospitalized COVID-19 patients under Interim Order ID# 316575. The company collaborates with ebbtides medical to expedite availability across Canada as COVID-19 cases rise. CytoSorb is designed to treat inflammation, enhancing outcomes in critical care and cardiac surgery.